Safimaltib

Safimaltib (JNJ-67856633) is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. Safimaltib in some cases lead to tumor stasis[1][2][3].

Product Specifications

CAS Number

[2230273-76-2]

Product Name Alternative

JNJ-67856633

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

MALT1

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/safimaltib.html

Purity

99.63

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C(C(F)(F)F)N(C2=CC=CC3=C2C=CNC3=O)N=C1)NC4=CC(C(F)(F)F)=NC=C4

Molecular Formula

C20H11F6N5O2

Molecular Weight

467.32

Precautions

H302, H315, H319

References & Citations

[1]Virtual meeting delivers first time drug structures|[2]A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants with NHL and CLL|[3]Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas